Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Dexmedetomidine or Lidocaine for Post Dural Puncture Headache
NCT06607861Phase 1Completed
- Sponsor
- Minia University
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexmedetomidine and lidocaine 10% oropharyngeal spray in post-dural puncture headache (PDPH) (3 arms), sponsored by Minia University. Primary endpoint: Pain severity at 120 hours. Started Jun 2024; status: completed.
02
Drugs
dexmedetomidinelidocaine 10% oropharyngeal spray
03
Conditions
post-dural puncture headache (PDPH)
Beyond the preview
Go deeper on NCT06607861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607861.